Bristol-Myers Squibb Company (BMS) engages in the discovery, development, license, manufacture, marketing, distribution, and sale of pharmaceutical and other health care products. The company primarily operates in three segments: Pharmaceuticals, Nutritionals, and Other Healthcare. The Pharmaceuticals segment provides branded pharmaceutical products for cardiovascular, virology, including human immunodeficiency virus, infectious diseases, oncology, affective disorders, and metabolics. It offers its products primarily to wholesalers, retail pharmacies, hospitals, government entities, and the medical professionals. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products, including a line of ENFAMIL products. The nutritional products are generally sold by wholesalers and retailers to healthcare professionals. The company’s Other Healthcare segment consists of ConvaTec, Medical Imaging, and Consumer Medicines businesses. ConvaTec provides ostomy, and wound and skin care products. Medical Imaging offers cardiovascular imaging products, including radiopharmaceuticals and ultra-sound agents. Consumer Medicines provides consumer health care products for headache relief, analgesics, cold, cough, flu, and moisturizers, as well as for diabetics. BMS has strategic alliances with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; and Sankyo Company, Ltd. The company through a collaboration agreement with Merck & Co., Inc. codevelops and copromotes muraglitazar, its dual peroxisome proliferator activated receptor agonist. The company was incorporated in 1933 under the name Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers is headquartered in the New York City.